{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:44:09Z","timestamp":1781185449668,"version":"3.54.1"},"reference-count":28,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2022,7,1]]},"DOI":"10.1248\/bpb.b22-00268","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T22:14:53Z","timestamp":1656627293000},"page":"940-947","source":"Crossref","is-referenced-by-count":4,"title":["Proarrhythmia Risk Assessment Using Electro-Mechanical Window in Human iPS Cell-Derived Cardiomyocytes"],"prefix":"10.1248","volume":"45","author":[{"given":"Shota","family":"Yanagida","sequence":"first","affiliation":[{"name":"Division of Pharmacology, National Institute of Health Sciences"},{"name":"Division of Pharmaceutical Sciences, Graduated School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Satsuka","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, National Institute of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayo","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, National Institute of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, Graduated School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Kanda","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, National Institute of Health Sciences"},{"name":"Division of Pharmaceutical Sciences, Graduated School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN. Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework. <i>Nat. Rev. Drug Discov.<\/i>, <b>13<\/b>, 419\u2013431 (2014).","DOI":"10.1038\/nrd4309"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Stockbridge N, Morganroth J, Shah RR, Garnett C. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated? <i>Drug Saf.<\/i>, <b>36<\/b>, 167\u2013182 (2013).","DOI":"10.1007\/s40264-013-0016-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Blinova K, Dang Q, Millard D, <i>et al.<\/i> International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. <i>Cell Reports<\/i>, <b>24<\/b>, 3582\u20133592 (2018).","DOI":"10.1016\/j.celrep.2018.08.079"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ando H, Yoshinaga T, Yamamoto W, Asakura K, Uda T, Taniguchi T, Ojima A, Shinkyo R, Kikuchi K, Osada T, Hayashi S, Kasai C, Miyamoto N, Tashibu H, Yamazaki D, Sugiyama A, Kanda Y, Sawada K, Sekino Y. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes. <i>J. Pharmacol. Toxicol. Methods<\/i>, <b>84<\/b>, 111\u2013127 (2017).","DOI":"10.1016\/j.vascn.2016.12.003"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Yanagida S, Satsuka A, Hayashi S, Ono A, Kanda Y. Comprehensive cardiotoxicity assessment of COVID-19 treatments using human-induced pluripotent stem cell-derived cardiomyocytes. <i>Toxicol. Sci.<\/i>, <b>183<\/b>, 227\u2013239 (2021).","DOI":"10.1093\/toxsci\/kfab079"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kanda Y, Yamazaki D, Osada T, Yoshinaga T, Sawada K. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update. <i>J. Pharmacol. Sci.<\/i>, <b>138<\/b>, 233\u2013239 (2018).","DOI":"10.1016\/j.jphs.2018.10.010"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Colatsky T, Fermini B, Gintant G, Pierson JB, Sager P, Sekino Y, Strauss DG, Stockbridge N. The Comprehensive <i>in Vitro<\/i> Proarrhythmia Assay (CiPA) initiative\u2014update on progress. <i>J. Pharmacol. Toxicol. Methods<\/i>, <b>81<\/b>, 15\u201320 (2016).","DOI":"10.1016\/j.vascn.2016.06.002"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) van der Linde HJ, Van Deuren B, Somers Y, Loenders B, Towart R, Gallacher DJ. The electro-mechanical window: a risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias. <i>Br. J. Pharmacol.<\/i>, <b>161<\/b>, 1444\u20131454 (2010).","DOI":"10.1111\/j.1476-5381.2010.00934.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Guns PJ, Johnson DM, Van Op Den Bosch J, Weltens E, Lissens J. The electro-mechanical window in anaesthetized guinea pigs: A new marker in screening for Torsade de Pointes risk. <i>Br. J. Pharmacol.<\/i>, <b>166<\/b>, 689\u2013701 (2012).","DOI":"10.1111\/j.1476-5381.2011.01795.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Morissette P, Regan C, Fitzgerald K, Gerenser P, Travis J, Wang S, Fanelli P, Sannajust F. Shortening of the electromechanical window in the ketamine\/xylazine-anesthetized guinea pig model to assess pro-arrhythmic risk in early drug development. <i>J. Pharmacol. Toxicol. Methods<\/i>, <b>81<\/b>, 171\u2013182 (2016).","DOI":"10.1016\/j.vascn.2016.06.003"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Shah RR, Maison-Blanche P, Duvauchelle T, Robert P, Denis E. Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>71<\/b>, 1451\u20131459 (2015).","DOI":"10.1007\/s00228-015-1959-z"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yanagida S, Satsuka A, Hayashi S, Ono A, Kanda Y. Chronic cardiotoxicity assessment of BMS-986094, a guanosine nucleotide analogue, using human iPS cell-derived cardiomyocytes. <i>J. Toxicol. Sci.<\/i>, <b>46<\/b>, 359\u2013369 (2021).","DOI":"10.2131\/jts.46.359"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kanda Y, Satsuka A, Hayashi S, Hagiwara-Nagasawa M, Sugiyama A. Assessment of contractility in human iPS cell-derived cardiomyocytes using motion vector analysis. <i>Methods Mol. Biol.<\/i>, <b>2320<\/b>, 151\u2013160 (2021).","DOI":"10.1007\/978-1-0716-1484-6_15"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hayakawa T, Kunihiro T, Ando T, Kobayashi S, Matsui E, Yada H, Kanda Y, Kurokawa J, Furukawa T. Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology. <i>J. Mol. Cell. Cardiol.<\/i>, <b>77<\/b>, 178\u2013191 (2014).","DOI":"10.1016\/j.yjmcc.2014.09.010"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM. MICE models: superior to the HERG model in predicting torsade de pointes. <i>Sci. Rep.<\/i>, <b>3<\/b>, 2100 (2013).","DOI":"10.1038\/srep02100"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. <i>Heart Rhythm<\/i>, <b>8<\/b>, 1281\u20131290 (2011).","DOI":"10.1016\/j.hrthm.2011.03.045"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D. Simulation of multiple ion channel block provides improved early prediction of compounds\u2019 clinical torsadogenic risk. <i>Cardiovasc. Res.<\/i>, <b>91<\/b>, 53\u201361 (2011).","DOI":"10.1093\/cvr\/cvr044"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Redfern WS, Carlsson L, Davis A, Lynch WG, Mackenzie I, Palethorpe S, Siegl P, Strang I, Sullivan A, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. <i>Cardiovasc. Res.<\/i>, <b>58<\/b>, 32\u201345 (2003).","DOI":"10.1016\/S0008-6363(02)00846-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Skinner M, Hale E, Ceuppens P, Pollard C. Differentiating multichannel block on the guinea pig ECG: use of T<sub>peak<\/sub>-T<sub>end<\/sub> and J-T<sub>peak<\/sub>. <i>J. Pharmacol. Toxicol. Methods<\/i>, <b>111<\/b>, 107085 (2021).","DOI":"10.1016\/j.vascn.2021.107085"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ton AT, Nguyen W, Sweat K, Miron Y, Hernandez E, Wong T, Geft V, Macias A, Espinoza A, Truong K, Rasoul L, Stafford A, Cotta T, Mai C, Indersmitten T, Page G, Miller PE, Ghetti A, Abi-Gerges N. Arrhythmogenic and antiarrhythmic actions of late sustained sodium current in the adult human heart. <i>Sci. Rep.<\/i>, <b>11<\/b>, 12014 (2021).","DOI":"10.1038\/s41598-021-91528-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Hu HJ, Wang SS, Wang YX, Liu Y, Feng XM, Shen Y, Zhu L, Chen HZ, Song M. Blockade of the forward Na<sup>+<\/sup> \/Ca<sup>2+<\/sup> exchanger suppresses the growth of glioblastoma cells through Ca<sup>2+<\/sup> -mediated cell death. <i>Br. J. Pharmacol.<\/i>, <b>176<\/b>, 2691\u20132707 (2019).","DOI":"10.1111\/bph.14692"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Watanabe Y, Kimura J. Blocking effect of bepridil on Na<sup>+<\/sup>\u2009\/Ca<sup>2+<\/sup> exchange current in guinea pig cardiac ventricular myocytes. <i>Jpn. J. Pharmacol.<\/i>, <b>85<\/b>, 370\u2013375 (2001).","DOI":"10.1254\/jjp.85.370"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Lemoine MD, Mannhardt I, Breckwoldt K, Prondzynski M, Flenner F, Ulmer B, Hirt MN, Neuber C, Horv\u00e1th A, Kloth B, Reichenspurner H, Willems S, Hansen A, Eschenhagen T, Christ T. Human iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show physiological upstroke velocity and sodium current density. <i>Sci. Rep.<\/i>, <b>7<\/b>, 5464 (2017).","DOI":"10.1038\/s41598-017-05600-w"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Gupta T, Khera S, Kolte D, Aronow WS, Iwai S. Antiarrhythmic properties of ranolazine: a review of the current evidence. <i>Int. J. Cardiol.<\/i>, <b>187<\/b>, 66\u201374 (2015).","DOI":"10.1016\/j.ijcard.2015.03.324"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Vaidyanathan R, Markandeya YS, Kamp TJ, Makielski JC, January CT, Eckhardt LL. IK1-enhanced human-induced pluripotent stem cell-derived cardiomyocytes: An improved cardiomyocyte model to investigate inherited arrhythmia syndromes. <i>Am. J. Physiol. Heart Circ. Physiol.<\/i>, <b>310<\/b>, H1611\u2013H1621 (2016).","DOI":"10.1152\/ajpheart.00481.2015"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Li M, Kanda Y, Ashihara T, Sasano T, Nakai Y, Kodama M, Hayashi E, Sekino Y, Furukawa T, Kurokawa J. Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs. <i>J. Pharmacol. Sci.<\/i>, <b>134<\/b>, 75\u201385 (2017).","DOI":"10.1016\/j.jphs.2017.05.004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Gao Y, Xue X, Hu D, Liu W, Yuan Y, Sun H, Li L, Timothy KW, Zhang L, Li C, Yan GX. Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome. <i>Circ. Arrhythm. Electrophysiol.<\/i>, <b>6<\/b>, 614\u2013622 (2013).","DOI":"10.1161\/CIRCEP.113.000092"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ahmed RE, Anzai T, Chanthra N, Uosaki H. A brief review of current maturation methods for human induced pluripotent stem cells-derived cardiomyocytes. <i>Front. Cell Dev. Biol.<\/i>, <b>8<\/b>, 178 (2020).","DOI":"10.3389\/fcell.2020.00178"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/7\/45_b22-00268\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:29:28Z","timestamp":1715232568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/7\/45_b22-00268\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b22-00268","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"article-number":"b22-00268"}}